Saisho Yoshifumi, Komiya Naoko, Hirose Hiroshi
Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Diabetes Res Clin Pract. 2006 Nov;74(2):201-3. doi: 10.1016/j.diabres.2006.04.015. Epub 2006 Jun 5.
Although it has been reported that angiotensin II receptor blocker inhibited the formation and accumulation of advanced glycation endproducts (AGEs) in vitro and in vivo, whether it can do so clinically is unknown. We therefore examined the effect of valsartan on markers of oxidation and glycation.
We started 40mg/day valsartan treatment in 15 type 2 diabetic subjects with hypertension, and metabolic parameters, lipid peroxide, paraoxonase activity, platelet-activating factor acethylhydrolase activity, AGEs and urine 8-isoprostane were measured at baseline and after 3 and 6 months of treatment.
Even after valsartan treatment, the blood pressure level of the patients did not change during the study. However, AGEs and urine 8-isoprastane levels had decreased at 6 months (p<0.05 and <0.01) as well as urine microalbumin level (p<0.01), although other oxidative stress markers were unchanged.
In this study, low-dose valsartan treatment decreased serum AGEs level, whereas blood pressure level was unchanged. The effect of valsartan on AGEs might be a blood pressure-independent effect in type 2 diabetic subjects.
尽管有报道称血管紧张素II受体阻滞剂在体外和体内均可抑制晚期糖基化终末产物(AGEs)的形成和积累,但在临床上是否如此尚不清楚。因此,我们研究了缬沙坦对氧化和糖基化标志物的影响。
我们对15名患有高血压的2型糖尿病患者开始每日40mg缬沙坦治疗,并在基线以及治疗3个月和6个月后测量代谢参数、脂质过氧化物、对氧磷酶活性、血小板活化因子乙酰水解酶活性、AGEs和尿8-异前列腺素。
即使在缬沙坦治疗后,患者的血压水平在研究期间也未发生变化。然而,6个月时AGEs和尿8-异前列腺素水平降低(p<0.05和<0.01),尿微量白蛋白水平也降低(p<0.01),尽管其他氧化应激标志物未改变。
在本研究中,低剂量缬沙坦治疗可降低血清AGEs水平,而血压水平未改变。缬沙坦对AGEs的作用可能是2型糖尿病患者中不依赖血压的效应。